Screening

Patients with complaints of dyspnea on exertion and chest pain, with or without dizziness, syncope, and signs of right heart failure of unknown cause, should be screened for PH. Various tests, which present a broad spectrum of sensitivity and specificity, can be used for the initial evaluation of patients suspected of having PH. Chest X-rays and electrocardiography (ECG), for instance, are tests that have low accuracy for the diagnosis of PH. Nevertheless, due to
group of authors found that a PA diameter > 33.2 mm has a 95% specificity for the diagnosis of PH (Figure 2b).[5]

**Echocardiography**

Echocardiography is the principal screening tool for PH. However, echocardiography is a test that has significant limitations, such as the fact that it is highly examiner-dependent and that a significant proportion of patients present with a poor acoustic window. Another limitation of echocardiography is that the estimation of PA systolic pressure (PASP) depends on the tricuspid regurgitant jet and right atrial pressure (RAP). In up to 10% of cases, it is impossible to measure the tricuspid regurgitant jet velocity and, consequently, to estimate PASP. Although some studies have shown a significant correlation between echocardiography findings and RHC values, one group of authors recently reported that the RAP and PASP values estimated by echocardiography differ significantly from those measured by RHC.[6] In that study, 65 patients referred for PH diagnosis or follow-up treatment underwent echocardiography and RHC one hour apart, meaning that the basal conditions of patients varied minimally. It was also shown that cardiac output (Qt) as measured by echocardiography is not useful and that echocardiography typically overestimates pressures. Therefore, PASP values as estimated by echocardiography should be used to screen for PH, rather than to diagnose it. In addition to PASP estimates, dilation and right ventricular dysfunction should be considered to constitute indirect signs of PH. Despite its limitations, echocardiography continues to be the principal screening tool for PH because it is a noninvasive and readily available test, as well as being useful in identifying left heart malformations and diseases.

Because right ventricular function plays a significant role in the prognosis of patients with PH, it is necessary to measure right ventricular function appropriately. The characteristics of the right ventricle (RV) are quite different from those of the left ventricle (LV). Unlike the LV, which has thick, cone-shaped walls, the RV has thin, semilunar or crescent-shaped walls, and the myocardial mass of the RV is significantly lower and more trabecular than is that of the LV. The contraction pattern is also different; in the
RV, longitudinal contraction of the myocardial fibers predominates, whereas, in the LV, spiral movement predominates. Therefore, it does not seem sufficient or appropriate to evaluate right ventricular function with the same tools used to evaluate left ventricular function.

New techniques for a better estimation of right ventricular function have been studied. The determination of tricuspid annular plane systolic excursion (TAPSE) has been shown to be a useful tool. This technique calculates the degree to which the pulmonary valve ring is shifted, in relation to the right ventricular apex during systole. A study comparing TAPSE and RHC measurements for the evaluation of right ventricular function showed that the measurements correlated well. The authors found that a TAPSE < 1.8 cm showed good accuracy in detecting right ventricular dysfunction and designated it a prognostic marker, because survival rates were lower in patients with a TAPSE < 1.8 cm than in those with a TAPSE ≥ 1.8 cm.7

Other techniques for the evaluation of right ventricular function, such as the comparison between the right ventricular area at systole and that at diastole—designated right ventricular fractional area change—and the comparison between the right ventricular end-diastolic area and the left ventricular end-diastolic area, have been studied and might prove useful in patients with PH.

**Magnetic resonance imaging**

Advances in the techniques for acquiring and processing magnetic resonance imaging of the heart have allowed three-dimensional evaluation of the RV and detailed tomographic visualization of its morphology. Cardiac magnetic resonance imaging (CMRI) creates a clear distinction between the myocardium and intracavitary blood, presenting well-defined myocardial and endocardial borders.8 Because the RV presents the aforementioned particularities and CMRI allows a more detailed visualization of the RV, CMRI is currently considered the gold standard for a noninvasive evaluation of the RV.9,10 Studies in which CMRI was used to evaluate patients with PH showed that, when compared with control group patients, PH patients presented with a significant increase in end-systolic and end-diastolic volumes, as well as in right ventricular muscle mass, together with a significant reduction in right ventricular ejection fraction. Other studies have shown ventricular septal bowing, together with a reduction in the LV volume in early diastole, revealing impaired left ventricular function associated with right ventricular dysfunction.11 One group of authors demonstrated that the position of the septum, as determined by calculating its shift toward the LV, was accurate in predicting right ventricular systolic pressure.12 Even without the use of contrast enhancement, CMRI allows excellent visualization of the PA, and it is possible to assess PA compliance and flow by means of the phase-contrast technique. In patients with PH, PA compliance values are significantly lower.13 One study showed that measurements of pulsatility (which is related to compliance) can also correlate with the response to the NO test.14 The measurement of PA velocity and the time it takes to reach the maximum velocity..
to perform RHC to confirm the diagnosis of PH should be evaluated, because a definitive diagnosis of PH can only be established by invasive pressure measurements (Figure 3).

Since the last Brazilian consensus, there have been changes in the definition of PH. Before the meeting in Dana Point, CA, PH was defined as mean PA pressure (MPAP) $\geq$ 25 mmHg at rest or $\geq$ 30 mmHg during exercise, with pulmonary capillary pressure $\leq$ 15 mmHg. The group of specialists who reviewed the data that had been published up until the time of the meeting concluded that the data collected during exercise were extremely heterogeneous regarding the load used, the duration of the exercise, and the position of the patient during exercise, factors that might influence PA pressure measurements. Due to this lack of standardization, a decision was made to remove exercise-induced PH from the definition of PH. This does not mean that exercise-induced PH does not exist; it only means that the data collected to date are not sufficiently robust to provide a definition of exercise-induced PH. This underscores the importance of conducting new studies in this field in order to provide an appropriate definition of exercise-induced PH.

A review of 47 studies evaluating PA pressure in healthy volunteers showed that the MPAP at rest was $14.0 \pm 3.3$ mmHg. When individuals from different age brackets were compared, there was only a slight, less than significant, variation in the MPAP at rest. Normal MPAP at rest was then defined as $< 20$ mmHg. The

Diagnosis

If a patient suspected of having PH has been screened and signs consistent with increased pressure levels in the pulmonary circulation have been detected in the initial tests, the need

<table>
<thead>
<tr>
<th>Chart 1 - Hemodynamic definition of pulmonary hypertension.(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
</tr>
<tr>
<td>PH</td>
</tr>
<tr>
<td>Precapillary PH</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Postcapillary PH</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Passive (proportional)</td>
</tr>
<tr>
<td>Reactive (disproportional)</td>
</tr>
</tbody>
</table>

PH: pulmonary hypertension; MPAP: mean pulmonary artery pressure; PAOP: pulmonary artery occlusion pressure; Qt: cardiac output; PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; and TPG: transpulmonary gradient. \(^a\)Adapted from Badesh et al.\(^{21}\)
must be determined. The TPG is calculated be the difference between the MPAP and the PAOP. When this difference is \( \leq 12 \) mmHg, the increase in the MPAP is considered passive, which means that the increase in the MPAP is caused exclusively by cardiac involvement. If the TPG is > 12 mmHg, the increase in the MPAP is disproportionate to the increase in left ventricular pressure, indicating that there is pulmonary vascular remodeling or another associated cause of increased MPAP (Chart 1 and Figure 3).

The acute test with a vasodilator should be performed during the initial hemodynamic evaluation in patients with precapillary PH. The test can be performed with NO, prostacyclin, or adenosine. The result is considered positive when there is a reduction in the MPAP of \( \geq 10 \) mmHg.
and when values $\leq 40$ mmHg are observed. A positive acute test result predicts the clinical and hemodynamic response to calcium channel blockers.\(^{(21,22)}\)

After the presence of PH and its correct hemodynamic classification are confirmed by RHC, various tests should be performed in order to determine the specific etiology of PH. It should be highlighted that idiopathic PH is a differential diagnosis, and it is fundamental to follow an appropriate flowchart to facilitate the diagnostic investigation (Figure 4).

**Classification**

There have been various changes in the clinical classification of PH. Although the basic structure of the 2003 Venice classification—five principal groups and their respective subgroups—was maintained, pathologies have been moved from one group or subgroup to another. In addition, some new groups or subgroups have been created, whereas others have been eliminated. These changes are described below. The former and current classifications are compared in Chart 2.\(^{(23)}\)

The first group is still designated “pulmonary arterial hypertension” (PAH) and is divided into two subgroups: “idiopathic” and “heritable” (formerly “familial”). There have been no changes in subgroup 1.1, idiopathic PAH (IPAH), which still comprises the sporadic cases in which no risk factors for PAH are detected or in which

![Flowchart for the diagnosis of the etiology of pulmonary hypertension. CTEPH: chronic thromboembolic pulmonary hypertension; PVOD: pulmonary veno-occlusive disease; US: ultrasound; TEE: transesophageal echocardiogram; CMRI: cardiac magnetic resonance imaging; and OSAS: obstructive sleep apnea syndrome. Adapted from Galiè et al.\(^{(27)}\)](image-url)
**Chart 2** - Clinical classification of pulmonary hypertension established in Venice, Italy, in 2003, and the current classification, established in Dana Point, CA, USA, in 2008.

<table>
<thead>
<tr>
<th>Venice, 2003</th>
<th>Dana Point, 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Pulmonary arterial hypertension</td>
<td>1. Pulmonary arterial hypertension</td>
</tr>
<tr>
<td>1.1. Idiopathic</td>
<td>1.1. Idiopathic</td>
</tr>
<tr>
<td>1.2. Familial</td>
<td>1.2. Heritable</td>
</tr>
<tr>
<td>1.3. Associated with:</td>
<td>1.2.1. BMPR2</td>
</tr>
<tr>
<td>1.3.1. Collagen vascular diseases</td>
<td>1.2.2. ALK-1, endoglin (with or without hereditary hemorrhagic telangiectasia)</td>
</tr>
<tr>
<td>1.3.2. Congenital systemic-pulmonary shunts</td>
<td>1.2.3. Unknown</td>
</tr>
<tr>
<td>1.3.3. Portal hypertension</td>
<td>1.3. Drug- and toxin-induced</td>
</tr>
<tr>
<td>1.3.4. Infection with the human immunodeficiency virus</td>
<td>1.4. Associated with</td>
</tr>
<tr>
<td>1.3.5. Drugs/toxins</td>
<td>1.4.1. Connective tissue diseases</td>
</tr>
<tr>
<td>1.3.6. Others (thyroid diseases, hereditary hemorrhagic telangiectasia, hemoglobinopathies, Gaucher’s disease, myeloproliferative disorders, and splenectomy)</td>
<td>1.4.2. Human immunodeficiency virus infection</td>
</tr>
<tr>
<td>1.4. Associated with significant capillary or venous involvement:</td>
<td>1.4.3. Portal hypertension</td>
</tr>
<tr>
<td>1.4.1. Pulmonary veno-occlusive disease</td>
<td>1.4.4. Congenital heart diseases</td>
</tr>
<tr>
<td>1.4.2. Pulmonary capillary hemangiomatosis</td>
<td>1.4.5. Schistosomiasis</td>
</tr>
<tr>
<td>1.5. Persistent pulmonary hypertension of the newborn</td>
<td>1.4.6. Chronic hemolytic anemia</td>
</tr>
<tr>
<td>2. Pulmonary venous hypertension</td>
<td>1.5. Persistent pulmonary hypertension of the newborn</td>
</tr>
<tr>
<td>2.1. Left ventricular or left atrial heart disease</td>
<td>1. Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis</td>
</tr>
<tr>
<td>2.2. Left valvular heart disease</td>
<td>2. Pulmonary hypertension owing to left heart disease</td>
</tr>
<tr>
<td>3. Pulmonary hypertension associated with lung disease, hypoxemia, or both</td>
<td>2.1. Systolic dysfunction</td>
</tr>
<tr>
<td>3.1. COPD</td>
<td>2.2. Diastolic dysfunction</td>
</tr>
<tr>
<td>3.2. Interstitial lung disease</td>
<td>2.3. Valvular disease</td>
</tr>
<tr>
<td>3.3. Sleep-disordered breathing</td>
<td></td>
</tr>
<tr>
<td>3.4. Alveolar hypoventilation</td>
<td></td>
</tr>
<tr>
<td>3.5. Chronic exposure to high altitudes</td>
<td></td>
</tr>
<tr>
<td>3.6. Developmental abnormalities</td>
<td></td>
</tr>
<tr>
<td>4. Pulmonary hypertension due to embolic disease, chronic thrombotic disease, or both</td>
<td>3.1. COPD</td>
</tr>
<tr>
<td>4.1. Thromboembolic obstruction of proximal pulmonary arteries</td>
<td>3.2. Interstitial lung disease</td>
</tr>
<tr>
<td>4.2. Obstruction of distal pulmonary arteries</td>
<td>3.3. Other lung diseases with mixed restrictive and obstructive pattern</td>
</tr>
<tr>
<td>4.3. Nonthrombotic pulmonary embolism</td>
<td>3.4. Sleep-disordered breathing</td>
</tr>
<tr>
<td>(tumor, parasites, foreign body)</td>
<td>3.5. Alveolar hypoventilation disorders</td>
</tr>
<tr>
<td>5. Miscellaneous</td>
<td>3.6. Chronic exposure to high altitude</td>
</tr>
<tr>
<td>Sarcoïdosis, histiocytosis X, lymphangioleiomyomatosis, compression of pulmonary vessels (adenopathy, tumor, and fibrosing mediastinitis)</td>
<td>3.7. Developmental abnormalities</td>
</tr>
<tr>
<td>5. Pulmonary hypertension with unclear multifactorial mechanisms</td>
<td>4. Chronic thromboembolic pulmonary hypertension</td>
</tr>
<tr>
<td>5.1. Hematologic disorders: myeloproliferative disorders, splenectomy</td>
<td></td>
</tr>
<tr>
<td>5.2. Systemic disorders: sarcoïdosis, pulmonary</td>
<td></td>
</tr>
<tr>
<td>Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis</td>
<td></td>
</tr>
<tr>
<td>5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders</td>
<td></td>
</tr>
<tr>
<td>5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis</td>
<td></td>
</tr>
</tbody>
</table>

BMPR2: bone morphogenetic protein receptor, type 2; and ALK-1: activin receptor-like kinase-1. Adapted from Simonneau et al.\(^\text{23}\)
demonstrated that the clinical characteristics of patients with schistosomiasis and PH are similar to those of patients with IPAH.\textsuperscript{(29)} The other study demonstrated that 7.7\% of the patients with hepatosplenic schistosomiasis who were being treated at the University of São Paulo School of Medicine Hospital das Clínicas, located in the city of São Paulo, Brazil, had PH (4.6\% of whom had precapillary PH).\textsuperscript{(26)} Given the number of patients worldwide, schistosomiasis might become the leading cause of PH. Therefore, this change in the classification has a significant impact on Brazil and on all countries in which schistosomiasis is endemic. Concluding the changes in group 1, subgroup 1’ (read “one prime”) was created. This subgroup comprises pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis, because the histopathological features of these two entities have been shown to overlap. It is currently believed that they can represent different phases of the evolution of the same pathology. A decision was made to maintain the two entities in the group related to primarily arterial involvement, due to their degree of clinical response to the treatment with PAH-specific drugs, among other reasons.

Group 2 is designated “[PH] owing to left heart disease”, in order to highlight the causal relationship between cardiac involvement and the development of PH, because this is potentially the most common cause of PH. This group was subdivided into three subgroups: 2.1—systolic dysfunction; 2.2—diastolic dysfunction; and 2.3—valvular disease.

In group 3, the term “associated with” was changed to “owing to”, reinforcing the causal importance of pulmonary involvement. Therefore, group 3 is now designated “[PH] owing to lung disease and/or hypoxia”, and its subgroups are as follows: COPD; interstitial lung disease; sleep-disordered breathing; alveolar hypoventilation disorders; chronic exposure to high altitude; developmental abnormalities; and a new subgroup, designated “other pulmonary diseases with mixed restrictive and obstructive pattern”. The last subgroup comprises chronic bronchiectasis, cystic fibrosis, and a recently recognized syndrome in which fibrosis predominates in the lung bases and emphysema predominates in the lung apices. The prevalence of PH in patients with this syndrome is nearly
ideal type of contraception for patients with PH, it should be borne in mind that concomitant use of bosentan and oral contraceptives can reduce the effect of the latter. Patients in functional class III or IV, as well as those with hypoxemia (PaO$_2$ < 60 mmHg), should use supplemental oxygen if flying or visiting areas at altitudes above 1,500-2,000 m.\textsuperscript{27}

Supplemental oxygen therapy is indicated for patients with hypoxemia (PaO$_2$ < 60 mmHg) and can be considered for patients who present symptomatic benefit from the correction of hypoxemia during physical exertion. The use of diuretics is indicated for all patients who present with signs of hypervolemia.\textsuperscript{27}

The use of anticoagulants in patients with PH is controversial, because there have been no randomized controlled studies evaluating the effects of anticoagulation in these patients. The rationale for the indication of anticoagulation for these patients originates from the histopathological findings of microvascular thrombosis, activation of the coagulation system, and platelet dysfunction in patients with IPAH, which have led to the assumption that these patients present with a prothrombotic state. In a meta-analysis of the theme, conducted in 2006, the authors concluded that anticoagulation should be indicated, given that 5 of the 7 studies analyzed demonstrated that anticoagulation was beneficial. In the absence of any contraindications, the use of oral anticoagulants is indicated for patients with PH, with the objective of maintaining an international normalized ratio of 1.5–2.5. Attention should be given to patients with liver disease and scleroderma, because these patients might be at a higher risk for bleeding; likewise, attention should be given to the interaction between anticoagulants and the PAH-specific treatment. Some studies, for instance, have suggested that concomitant use of anticoagulants and sitaxsentan can increase the risk of bleeding.\textsuperscript{28}

**Group 1**

Most of the studies of PH treatment were conducted in patients with PAH; therefore, PH-specific treatment is, for the time being, restricted to group 1 patients. However, there has been no confirmation that all subgroups of patients with PAH respond to the specific drugs that are currently available. In general, the
evidence discussed here is restricted to patients with IPAH, heritable PAH, drug-induced PAH, PAH associated with connective tissue diseases, or PAH associated with congenital heart diseases. There is also some evidence for patients with HIV infection. However, for patients with portopulmonary hypertension, schistosomiasis, or hemolytic anemia, it is still impossible to indicate the use of the same drugs, and clinical studies specifically designed to investigate those indications are needed.

If the patient presents pulmonary vasoreactivity, as assessed by the acute test, treatment with a calcium channel blocker should be initiated, and, if there is a sustained clinical response, the drug should be maintained, together with supportive treatment. The survival rates in patients who respond to the use of a calcium channel blocker are significantly higher than in those who do not respond well to the drug. However, the use of calcium channel blockers in patients who do not present pulmonary vasoreactivity, as assessed by the acute test, can lead to a reduction in QT and systemic vascular resistance without a reduction in the MPAP or pulmonary vascular resistance (PVR). Therefore, the use of a calcium channel blocker is contraindicated for patients who do not present pulmonary vasoreactivity or those who have not undergone the acute test, due to the risk of clinical deterioration. The calcium channel blocker to be used can be nifedipine, diltiazem, or amlodipine. However, in patients with high heart rates, diltiazem is the drug of choice. The treatment should be initiated with low doses, which should be progressively increased in accordance with the tolerance limit of the patient.

The classes of specific drugs that are approved for use in PAH patients, that is, in group 1 patients, are as follows: prostacyclin analogues; phosphodiesterase-5 inhibitors; and endothelin receptor antagonists.

**Prostacyclin analogues**

Prostacyclin analogues constitute the first class of drugs to be approved for PH-specific treatment. Prostacyclin analogues can be administered intravenously, subcutaneously, orally, or by inhalation.

**Epoprostenol**

In an open randomized study conducted in 1996, clinical and hemodynamic improvements, as well as increased survival, were described in PAH patients who used epoprostenol in combination with conventional therapy (anticoagulation, diuretics, and oxygen therapy), when compared with those who used the conventional therapy in isolation. Although other studies have shown functional and hemodynamic improvements, the improvement in survival described in the aforementioned study has not been described elsewhere. Epoprostenol should be administered intravenously, through a tunneled catheter, and continuously, through a portable infusion pump, due to its short half-life. The most common side effects are jaw pain, flushing, diarrhea, nausea, and vomiting. Catheter-related complications, such as infection and thrombosis, as well as those related to the functioning of the equipment, have often been reported. Although epoprostenol is unavailable for use in Brazil, it is the only drug for functional class IV patients that has a grade of recommendation of A.

**Treprostinil**

Treprostinil is a prostacyclin analogue whose half-life is longer than that of epoprostenol, which allows treprostinil to be administered subcutaneously. In a randomized, placebo-controlled study, there was improvement in the symptoms, as well as slight but significant functional and hemodynamic improvements. Treprostinil has the advantage of not requiring an indwelling catheter, which avoids catheter-related complications. However, subcutaneous administration of treprostinil has been associated with pain at the injection site in 85% of the patients receiving the drug, and discontinuation of the drug is necessary in 8% of the cases. The speed at which the dose of the drug was increased was the principal causative factor for this side effect. Therefore, the dose should be increased slowly and progressively, and the site of injection should be changed every three days, in order to reduce this problem. The other side effects associated with epoprostenol can also occur in patients treated with treprostinil. In one study, sustained hemodynamic and symptomatic improvements were observed during a mean follow-up period of 26 months.
Treprostinil is also currently unavailable for use in Brazil. The administration of the drug through inhalation and continuous intravenous administration is currently being evaluated.

**Iloprost**

Iloprost is the prostacyclin analogue that is administered through inhalation. This route of administration has the advantage of acting on the pulmonary arteries that are in contact with ventilated regions; however, the drug must be inhaled 6–9 times a day and is commonly associated with the development of dry cough. Other side effects observed are the same as those of other prostacyclin analogues. A randomized, placebo-controlled study involving patients with PAH and CTEPH showed significant clinical improvement in a combined outcome that included physical exercise capacity, functional class in accordance with the New York Heart Association, and clinical deterioration for the group of patients treated with iloprost, who also presented hemodynamic stability during the study period.[31] Although it has been registered for use in Brazil, iloprost is not yet commercially available in the country.

**Beraprost**

Beraprost is the only prostacyclin analogue that is available for oral administration. Although two studies have demonstrated an improvement in the six-minute walk distance (6MWD), this response was not sustained, and there was no hemodynamic response. The side effects of the drug are the same as those of other prostacyclin analogues.[28] In an open, uncontrolled study conducted in Japan, long-acting beraprost (a preparation designated TRK-100STP) was reported to produce clinical, functional, and hemodynamic improvement, its future use being therefore promising.[32] Beraprost is also currently unavailable for use in Brazil.

**Phosphodiesterase-5 inhibitors**

Increased phosphodiesterase-5 in pulmonary arterioles and right ventricular myocytes has been demonstrated in patients with PH. The inhibition of this enzyme leads to an increase in the concentration of cyclic guanosine monophosphate, which promotes vasodilation, inhibits pulmonary artery remodeling due to its antiproliferative and pro-apoptotic effects, and seems to have a positive inotropic effect on the RV.[13] Phosphodiesterase-5 inhibitors reduce PVR and lead to an increase in Qt, and the use of these drugs has been associated with clinical and functional improvement in patients with PH.[34,35] Two phosphodiesterase-5 inhibitors have been approved for use in patients with PH: sildenafil, approved in 2005; and tadalafil, approved in 2009. One study compared the use of increasing doses of sildenafil (20, 40, and 80 mg), administered three times a day, with the use of placebo. The study showed a significant but not dose-dependent increase in the 6MWD, as well as a significant, dose-dependent reduction in PVR.[36] The benefits of tadalafil have been demonstrated in another study, in which increasing doses of the drug were also compared with placebo. Only the 40-mg dose correlated with a significant increase in the 6MWD, an improvement in the markers of quality of life, and a slight increase in the time to clinical worsening.[37] Phosphodiesterase inhibitors are relatively safe and well tolerated. Tadalafil has the advantage of being administered only once daily. The major side effects of the drugs are headache, nasal congestion, dyspepsia, flushing, muscle pain, and epistaxis. Phosphodiesterase inhibitors are metabolized in the liver, and the use of protease inhibitors, such as ritonavir and saquinavir, can increase their bioavailability, and care should therefore be taken when prescribing this class of drugs to HIV-infected patients. Visual disorders, such as blurred vision, color changes, and photosensitivity, have been described, principally in patients with diabetic neuropathy or anterior ischemic optic neuropathy. Dilated eye examination is recommended before starting the treatment with this type of medication.[27]

**Endothelin receptor antagonists**

Endothelin-1 levels are elevated in the lung tissue and plasma of patients with PAH and scleroderma. Endothelin-1 acts by binding to endothelin receptors (ETA and ETB), promoting vasoconstriction and smooth muscle cell proliferation. Bosentan is a nonselective endothelin receptor antagonist, meaning that it blocks types A and B, and has been shown to be beneficial for patients with IPAH and for those with PAH associated with collagen disease, leading to an increase in exercise capacity and
in the time to clinical worsening.\textsuperscript{[38]} Other studies have reinforced the beneficial effects of bosentan, as well as showing hemodynamic and functional improvements.\textsuperscript{[27,39]} One study showed that the use of bosentan in functional class II patients is also beneficial.\textsuperscript{[40]} The use of bosentan in these patients, who are less symptomatic, was shown to produce hemodynamic improvement and prevent clinical worsening.\textsuperscript{[40]} The drug is generally well tolerated, and its principal side effect is an increase in hepatic enzyme levels, which requires that liver function be monitored throughout the treatment. The treatment should be initiated at a dose of 62.5 mg, twice daily, and, if the drug is well tolerated, the dose should be increased to 125 mg, twice daily. Monitoring through blood workup is also indicated, due to a report of anemia associated with the use of the drug.\textsuperscript{[27]} Retrospective studies have also shown a reduction in the mortality associated with the use of endothelin receptor antagonists.

Another endothelin receptor antagonist is sitaxsentan, which is a specific inhibitor of the ETA receptor and has also been associated with better quality of life and functional capacity in patients with PH.\textsuperscript{[41]} An open study comparing patients receiving sitaxsentan with those receiving bosentan demonstrated that the patients receiving sitaxsentan showed a trend toward reduced clinical worsening and better tolerance, with a lower increase in hepatic enzyme levels. A subgroup analysis has suggested that patients with PAH associated with connective tissue disease benefit significantly more from sitaxsentan than from bosentan.\textsuperscript{[42]} The use of sitaxsentan significantly increases serum levels of dicumarol, requiring even closer monitoring of the coagulation profile during the treatment. This characteristic, together with case reports of complications related to the use of sitaxsentan, is what prevents this medication from being universally approved by the agencies that regulate the use of medications.

Yet another endothelin receptor antagonist is ambrisentan, which is also a selective ETA receptor antagonist and has been shown to produce a significant increase in the 6MWD and in the time to clinical worsening, as well as improving dyspnea and quality of life scores. It is of note that none of the patients who received treatment with ambrisentan presented with increased hepatic enzyme levels, and the drug also has the advantage of being administered only once daily. Another characteristic of the use of ambrisentan is the low interaction with other drugs, specifically with dicumarol and its derivatives, which allows safer concomitant use.\textsuperscript{[43]}

However, it should be highlighted that there have been no controlled studies to determine which of the endothelin receptor antagonists, if any, is the most effective.

\textbf{Combination therapy}

Although the therapeutic armamentarium for the treatment of PH has expanded greatly in recent years, a significant proportion of patients show no improvement or present clinical worsening during monotherapy. Until recently, there had been no studies confirming that the clinical response to combination therapy was effective or reporting that such therapy was well tolerated, although the concept of targeting different pathophysiological pathways was deemed logical in theory. Case reports and uncontrolled studies showed clinical improvement with and tolerance to the use of combination therapy. Consequently, randomized, placebo-controlled studies were conducted. Concomitant use of sildenafil in patients receiving epoprostenol was found to provide greater functional and hemodynamic improvement, as well as greater improvement in quality of life, together with an increase in the time to clinical worsening.\textsuperscript{[44]} Patients treated with the bosentan–epoprostenol combination showed a trend toward significant hemodynamic improvement, as well as greater improvement in quality of life, together with an increase in the time to clinical worsening.\textsuperscript{[44]} Patients treated with the bosentan–epoprostenol combination showed a trend toward significant hemodynamic improvement, as well as greater improvement in quality of life, together with an increase in the time to clinical worsening.\textsuperscript{[44]}
those with TPG $\geq$ 12 mmHg, should be included in studies designed to that end.

**Group 3**

Patients with parenchymal disease or hypoxemia should be primarily treated with oxygen therapy, and the treatment of the underlying disease should be optimized. The effectiveness of PH-specific drugs in this group of patients has yet to be confirmed, and the use of such drugs is currently contraindicated for these patients. When the MPAP is disproportionately high, that is, when parenchymal or functional involvement does not explain the degree of dyspnea and the MPAP at rest is higher than 40–45 mmHg, patients should be referred to a tertiary-care center, and the inclusion of such patients in studies is encouraged. However, PH-specific treatment should not be prescribed. It should be borne in mind that a finding of diastolic left ventricular dysfunction is not uncommon in these patients and might constitute another factor related to the pathogenesis of PH.

**Group 4**

In all patients with PH, CTEPH should be ruled out. A ventilation/perfusion lung scintigraphy should always be performed, as seen in the diagnostic algorithm, and, if the result is normal, CTEPH can be ruled out. Angiotomography of the chest is useful for the evaluation of pulmonary circulation; however, it should not be used as an isolated tool for determining the operability of CTEPH. Patients with a diagnosis of CTEPH should receive anticoagulants and be referred for surgery.

---

**Chart 3** - Parameters for the evaluation of the clinical severity of pulmonary arterial hypertension, as well as prognosis of the disease.

<table>
<thead>
<tr>
<th>Better prognosis</th>
<th>Determinants</th>
<th>Worse prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>No CTEPH</td>
<td>Clinical evidence of right ventricular failure</td>
<td>Yes</td>
</tr>
<tr>
<td>I or II</td>
<td>Functional class</td>
<td>IV</td>
</tr>
<tr>
<td>No</td>
<td>Syncpe</td>
<td>Yes</td>
</tr>
<tr>
<td>Slow</td>
<td>Symptom progression speed</td>
<td>Rapid</td>
</tr>
<tr>
<td>&gt; 500 m</td>
<td>6MWD</td>
<td>&lt; 300 m</td>
</tr>
<tr>
<td>Normal or stable</td>
<td>BNP</td>
<td>High or increased</td>
</tr>
<tr>
<td>Without pericardial effusion</td>
<td>Echocardiography</td>
<td>With pericardial effusion</td>
</tr>
<tr>
<td>TAPSE &gt; 15 mm</td>
<td></td>
<td>TAPSE &lt; 15 mm</td>
</tr>
<tr>
<td>RAP &lt; 8 mmHg</td>
<td>Hemodynamic function</td>
<td>RAP &gt; 15 mmHg</td>
</tr>
<tr>
<td>$\geq$ 2.5 L/min/m$^2$</td>
<td>CI</td>
<td>$\leq$ 2.0 L/min/m$^2$</td>
</tr>
</tbody>
</table>

6MWD: six-minute walk distance; BNP: brain natriuretic peptide; TAPSE: tricuspid annular plane systolic excursion; RAP: right atrial pressure; and CI: cardiac index. *Adapted from Galić et al.*

---

The use of combination therapy was therefore shown to be safe and effective. In cases in which the clinical response is inadequate or in which there is deterioration during monotherapy, concomitant use of another class of drugs should be indicated. Combination therapy can be initiated at the beginning of the treatment in cases in which the initial presentation is extremely severe. However, further studies are needed in order to confirm the true benefit of this approach.
to a tertiary-care center for the evaluation of the possibility of surgery. If the obstruction is operable, such patients should be referred for thromboendarterectomy. When a surgical intervention is contraindicated or cannot be performed, or when the patient presents with PH after thromboendarterectomy, the use of specific treatment seems beneficial.

A recent randomized controlled study demonstrated the hemodynamic benefit of the use of bosentan in patients with inoperable CTEPH, although the effect of the drug on functional capacity was not significant. The use of sildenafil in patients with CTEPH for whom surgery is contraindicated has previously been described in a case series. In addition, an open uncontrolled study conducted in 2007 and involving 104 patients showed good patient tolerance to the drug and a reduction in PVR, as well as improved function and 6MWD. A small-scale but placebo-controlled study showed improved quality of life, as well as hemodynamic and functional improvement, in patients with residual PH after thromboendarterectomy or with distal CTEPH. The decision to use specific medication in patients with CTEPH who cannot undergo surgery or who present with residual PH after surgical intervention should be made after an adequate evaluation of the case in a referral center, in order to rule out the hypothesis that these patients will benefit from the surgical approach. In addition, these patients should remain under close clinical monitoring.

---

**Figure 5** - Treatment algorithm. FC: functional class. Adapted from Barst et al.
Treatment initiation and follow-up

After it has been decided whether patients should receive specific treatment, it is important to establish the clinical severity of the initial presentation of the disease. The fact that certain prognostic markers are major indicators of disease severity in patients with PH has been established in the literature. The following have been associated with a worse prognosis: functional classes III and IV; an increase in brain natriuretic peptide (BNP) or N-terminal-pro-BNP levels; 6MWD < 330 m; maximal oxygen uptake during the cardiopulmonary test < 12 mL/min/kg; and hemodynamic variables (RAP > 8 mmHg and cardiac index ≤ 2.0 L/min/m²). Patients with markers of severity should be considered candidates for intravenous therapy in countries where this treatment is available. In localities where intravenous therapy is unavailable, combination therapy can be given at the initiation of treatment. However, it should be highlighted that there have been no clinical studies validating this approach; nevertheless, this approach has been considered in the latest international algorithms (Chart 3).

After the initiation of treatment, patients should be reevaluated, generally every 3-4 months, through analysis of the symptoms, physical examination findings, 6MWD, and BNP levels, in order to assess the response to treatment and decide the course of action. In localities where the 6MWT cannot be performed in a corridor, functional evaluation can be performed by means of a treadmill 6MWT, a protocol that has previously been validated for use in patients with PH. If patients present clinical improvement or stabilization, as well as improvement or stabilization of the aforementioned markers, the treatment should be maintained; otherwise, an investigation should be performed in order to find the cause of treatment failure and avoid clinical deterioration. Infection, dietary noncompliance (excessive ingestion of salt or fluids), or the inappropriate use of the drugs are common causes of decompensation. If an evident cause is not found, a new hemodynamic evaluation can be performed, and, if hemodynamic worsening is confirmed, the specific treatment should be optimized by increasing the dose or adding another class of drugs. Patients who present with progressive worsening despite the optimized clinical treatment should be referred for an evaluation for lung transplantation (Figure 5).

Future perspectives

There have been significant advances in recent years, and existing concepts, the levels of evidence of which had not been sufficient to allow further extrapolations, have been consolidated, making it possible to construct new diagnostic and therapeutic algorithms. The prospect of effective therapeutic alternatives for the various PH groups is excellent, and new pathophysiological pathways with therapeutic potential have been discovered, providing the spark for the development of new classes of drugs that might be added to the existing therapeutic armamentarium. This development has always been based on research, of increasing quality, which generates increasingly robust evidence. In the coming years, the expectation is that this characteristic will be increasingly present in the field of PH.

References


---

About the authors

Susana Hoette
Pulmonologist. Pulmonary Hypertension Group, Department of Pulmonology, Instituto do Coração, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo – InCor/HCFMUSP, Heart Institute/University of São Paulo School of Medicine Hospital das Clínicas – São Paulo, Brazil.

Carlos Jardim
Attending Physician. Pulmonary Hypertension Group, Department of Pulmonology, Instituto do Coração, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo – InCor/HCFMUSP, Heart Institute/University of São Paulo School of Medicine Hospital das Clínicas – São Paulo, Brazil.

Rogério de Souza
Tenured Professor. Department of Pulmonology, Instituto do Coração, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo – InCor/HCFMUSP, Heart Institute/University of São Paulo School of Medicine Hospital das Clínicas – São Paulo, Brazil.